on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 disclosure regarding its position in Avadel Pharmaceuticals plc. This document, dated December 18, 2025, details Vanguard's interests in Avadel's securities under Irish takeover legislation. Specifically, Vanguard controls 5,781,803 ordinary shares, representing 5.94% of Avadel's share capital. This disclosure is made under Rule 8.3 of the Irish Takeover Panel Act.
The filing reveals that Vanguard recently conducted trades involving Avadel's US$0.01 ordinary shares. On December 17, 2025, the firm purchased 72,418 shares and sold 3,744 shares, both at a price of 21.40 USD per unit. No cash-settled or stock-settled derivatives transactions were reported.
Vanguard indicated that there are no indemnity arrangements or agreements concerning options or derivatives related to these securities.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news